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Abstract
Tumor cell death is modulated by an intrinsic cell death pathway controlled by the pro- and anti-apoptotic members of the
Bcl-2 family. Up-regulation of anti-apoptotic Bcl-2 family members has been shown to suppress cell death in pre-clinical
models of human cancer and is implicated in human tumor progression. Previous gain-of-function studies in the RIP1-Tag2
model of pancreatic islet carcinogenesis, involving uniform or focal/temporal over-expression of Bcl-xL, demonstrated
accelerated tumor formation and growth. To specifically assess the role of endogenous Bcl-x in regulating apoptosis and
tumor progression in this model, we engineered a pancreatic b-cell-specific knockout of both alleles of Bcl-x using the Cre-
LoxP system of homologous recombination. Surprisingly, there was no appreciable effect on tumor cell apoptosis rates or
on tumor growth in the Bcl-x knockout mice. Other anti-apoptotic Bcl-2 family members were expressed but not
substantively altered at the mRNA level in the Bcl-x-null tumors, suggestive of redundancy without compensatory
transcriptional up-regulation. Interestingly, the incidence of invasive carcinomas was reduced, and tumor cells lacking Bcl-x
were impaired in invasion in a two-chamber trans-well assay under conditions mimicking hypoxia. Thus, while the function
of Bcl-x in suppressing apoptosis and thereby promoting tumor growth is evidently redundant, genetic ablation implicates
Bcl-x in selectively facilitating invasion, consistent with a recent report documenting a pro-invasive capability of Bcl-xL upon
exogenous over-expression.
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Introduction
For all cancerous lesions to increase in mass and malignant
potential, cell proliferation must outstrip cell death [1]. To this
end, human tumors engage or disengage a variety of pathways to
escape or minimize apoptosis. The necessity to down-modulate
apoptosis also stems from the fact that activating mutations in
oncogenes, as well as overexpression of wild-type oncogene alleles,
evoke not only hyperproliferation, but also cell death [2–4]. A
considerable body of evidence supports the proposition that,
without some degree of suppression of apoptosis, oncogene-
expressing cells cannot progress past relatively small, pre-
malignant proliferative lesions [1,5].
The first direct genetic connection between modulation of
apoptosis and tumor growth came from the discovery that
expression of the Bcl-2 gene was dysregulated via chromosomal
translocation in follicular lymphoma, and that this gene is
homologous to the C. elegans regulator of cell death, ced-9 [6–9].
Bcl-2 proved to be the prototype of a family of structurally related
apoptotic regulators, divided into two sub-groups that alternatively
suppress or induce apoptosis [10]. The anti-apoptotic arm of the
Bcl-2 family includes Bcl-2, Bcl-x (multiple anti-apoptotic splice
variants), Bcl-w, A1, Mcl-1 and Boo [10–12]. Activation of
apoptosis in response to oncogene-induced hyperproliferation has
been described in a variety of genetically engineered mouse
models of cancer, and in particular in two models of pancreatic
neuroendocrine islet cell cancer. In one such model, RIP1-Tag2
[13,14], SV40 T-antigens are constitutively expressed in the b-cells
of the endocrine pancreas under control of the rat insulin
promoter, resulting in a multistage pathway to invasive carcinoma
that is stochastic in nature and temporally protracted. At 2–3
weeks of age, the normal post-natal developmental proliferation of
islet cells tapers off, and in adult mice there is a relatively slow
turnover of b-cells, with a low proliferation rate offset by a low
apoptotic rate, which results in a very modest increase in b-cell
mass with age. In contrast, the b-cells of RIP1-Tag2 islets begin
hyperproliferating at 3–4 weeks of age along with a concomitant
activation of apoptosis. An early study reported that apoptosis
peaked at the angiogenic islet stage but was significantly down-
modulated in tumors, suggesting that resistance to cell death was a
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[15]. A more recent study of this model has shown that down-
modulation is not always the case, in that late-stage tumors
(including invasive carcinomas) in the current backcross genera-
tions typically have apoptotic rates similar to those of angiogenic
islets, suggesting a more subtle phenomena at play in expansive
tumor growth (ref [16]). Two well-defined suppressors of apoptosis
have been identified in this model: functional inactivation of p53
via large T-antigen expression, and up-regulation of the survival
factor IGF-II [17,18]. Genetic studies involving crosses to an IGF-
II null allele indicated that it largely functions as a survival factor
in this model, in that absence of IGF-II evoked much increased
(56) apoptotic rates in hyper-proliferative lesions, and the small
tumors arising had a less malignant cellular phenotype; notably,
the proliferation rate remained unchanged [18,19].
A demonstration that anti-apoptotic members of the Bcl-2
family can modulate cell-death in this model came from
experimental over-expression of Bcl-xL in b-cells via the rat insulin
promoter (RIP-Bcl-xL), which resulted in suppressed apoptosis and
an increase in tumor burden, along with a general ‘‘acceleration’’
of the tumor pathway [15]. More recently, the same RIP-Bcl-xL
transgene has also been shown to suppress apoptosis in another
mouse model of islet cell carcinoma, in which a myc fusion
protein, myc
TAM, was expressed in the b-cells under the control of
the rat insulin promoter [20]. Myc
TAM is only active in the
presence of tamoxifen, allowing for inducible and reversible gene
expression. Postnatal treatment of mice with tamoxifen results in a
rapid induction of myc
TAM expression concomitant with hyper-
proliferation of the b-cells. Interestingly, this hyper-proliferation
was accompanied by massive b-cell apoptosis that resulted in islet
involution within 6–10 days. Over-expression of Bcl-xL via the
same RIP-Bcl-xL transgene suppressed this apoptosis, resulting in
an increase in b-cell mass and a rapid progression to invasive
carcinomas. Thus, in two different transgenic mouse models of
islet cell carcinoma, elicited by two functionally distinct oncopro-
teins, over-expression of Bcl-xL suppresses apoptosis, resulting in
accelerated tumor formation. The results indicate that the
apoptosis observed in these tumor types is, at least in part,
mediated by the mitochondrial death pathway. In this report, we
explore the role that endogenous Bcl-x plays in modulating
apoptosis and tumor growth in the RIP1-Tag2 model via targeted
deletion of the gene in the oncogene-expressing b-cells using the
Cre/loxP system.
Results
Bcl-x expression in RIP1-Tag2 islet cell carcinogenesis
In situ hybridization with a pan-isoform probe to pancreatic
tissue sections from RIP1-Tag2 mice previously suggested that Bcl-
x mRNA was modestly up-regulated in tumors relative to
precursor lesions [15]. To confirm that Bcl-x is appreciably
expressed at the protein level during islet tumorigenesis, we went
on to assess the levels of Bcl-x protein by Western blotting using
lysates from normal islets and from the discrete stages of
pancreatic islet tumorigenesis in RIP1-Tag2 mice. As indicated
in Figure 1, a band migrating at 27 kDa consistent with the Bcl-xL
isoform was detected at similar levels in normal islets and in the
three neoplastic stages. In addition, a slightly faster migrating
band, potentially corresponding to the alternative splice variant
Bcl-xb [21,22], was detected in the angiogenic islet and tumor
stage but not normal islets or the hyperplastic islet stage. Thus the
overall levels of Bcl-x protein are modestly elevated in the
angiogenic islet and tumor stages.
Generating a b-cell specific gene knockout of bcl-x
To assess the functional role of Bcl-x in RIP1-Tag2 tumori-
genesis, we inactivated the Bcl-x gene in the b-cells of the
endocrine pancreas using the Cre/loxP system of homologous
recombination. The RIP-Cre line employed expresses Cre in
approximately 82% of the b-cells, mediating efficient recombina-
tion at loxP sites [23,24]. The ‘‘floxed’’ allele of Bcl-x, Bcl-x
fl/fl,i n
which exons 1 and 2 are flanked by loxP sites, has been shown to
be an efficient substrate for the Cre recombinase, producing a null
allele following recombination in other tissues [23–25]. We first
generated RIP-Cre, Bcl-x
fl/fl mice (and various control genotypes)
lacking the oncogene, and aged them out to .12 wks to assess
possible effects on b cell development and homeostasis. RIP-Cre;
Bcl-x
fl/fl and Bcl-x
fl/fl mice were born in expected Mendelian ratios,
and reached adulthood without early lethality or overt pathology.
We examined H&E stained pancreatic sections from RIP-Cre:Bcl-
x
fl/fl, and Cre-negative control mice using light microscopy. No
obvious difference in islet size, distribution, or number was
observed in a double-blind examination of these sections
(Figure 2A). The results imply that b-cell development and islet
morphogenesis were substantively normal in the absence of Bcl-x
function, although subtle physiological effects cannot be excluded
by this analysis. An alternative explanation for the lack of overt
phenotype in RIP-Cre; Bcl-x
fl/fl mice would be that the b-cells with
deleted Bcl-x died, and thus the normal islets observed were
derived from non-recombined, ‘‘escaper’’ b-cells that did not
express the transgene-derived Cre. To assess this possibility, we
isolated genomic DNA from pools of islets isolated from RIP-Cre;
Bcl-x
fl/fl mice and conducted PCR analysis with primers that
would amplify and distinguish a recombined allele from a non-
recombined allele (Figure 2B). Efficient recombination was
detected in RIP-Cre; Bcl-x
fl/fl islets. As expected, the recombined
allele was not detected in controls lacking the RIP-Cre transgene
(or in spleen from RIP-Cre; Bcl-x
fl/fl mice, where Cre is not
expressed).
Assessing the functional role of Bcl-x in RIP1-Tag2
tumorigenesis
To investigate the role of Bcl-x in modulating apoptosis during
RIP1-Tag2 tumorigenesis, we generated compound mice that
were homozygous for the Bcl-x
fl/fl allele and either carried both the
RIP1-Tag2 and the RIP-Cre transgenes, or just the RIP1-Tag2
transgene. Additional controls included mice that carried the
Figure 1. Bcl-x expression during RIP1-Tag2 tumor progres-
sion. Protein extracts from pools of normal, non-transgenic islets (N),
hyperplastic islets (H), angiogenic islets (A), and tumors (T) from RIP1-
Tag2 mice were immunoblotted with antibodies to Bcl-x and b-actin as
loading control. The 27 kDa band represents Bcl-xL; the faster migrating
band present in angiogenic islet and tumor extracts may represent the
alternative splice variant, Bcl-xb.
doi:10.1371/journal.pone.0004455.g001
Bcl-x and Islet Cell Tumors
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fl/fl mice exhibit normal islet morphology and efficient Bcl-x recombination. (A) H&E stained pancreatic sections from
12 week old mice of the following genotypes: Bcl-x
+/+; RIP-Cre;Bcl-x
+/+; and RIP-Cre;Bcl-x
fl/fll. Multiple sections of each of the animals depicted in
photomicrographs were examined. (B) Genomic DNA from pools of pancreatic islets was isolated from mice of distinct genotypes. PCR was carried
out using a primer that binds upstream of the 59 loxP site and another primer that binds 39 to the downstream loxP site. The PCR fragment of the
non-recombined allele and the recombined allele are 2.9 kb and 150 bp, respectively. Pancreatic islets were isolated (Materials and Methods) from 4–
6 animals of each genotype and pooled.
doi:10.1371/journal.pone.0004455.g002
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+/+ or Bcl-x
fl/+ alleles. We
aged out cohorts of these mice to 13 weeks of age, and quantified
both tumor burden (volume) and tumor number. The targeted
knockout of Bcl-x did not result in a significant difference in tumor
burden (Figure 3A). This essentially ‘‘wild-type’’ tumor burden in
the knockout animals was accompanied by an approximately 40%
decrease in tumor number; however, this effect did not reach
statistical significance (Figure 3B). To determine if this lack of
overt phenotypic effect on tumor growth was also reflected in the
apoptotic rate, we performed TUNEL assays on formalin-fixed
paraffin sections from RIP1-Tag2; RIP-Cre; Bcl-x
fl/fl and RIP1-
Tag2; Bcl-x
fl/fl animals. As suggested by the tumor burden and
tumor number data, there was no significant difference in the
apoptotic rate in tumors from ‘‘knockout’’ versus control animals
(Figure 3C).
To verify that Bcl-x was efficiently deleted in the tumors arising in
RIP1-Tag2; RIP-Cre; Bcl-x
fl/fl mice, we monitored recombination
using a PCR-based assay on genomic DNA from 12 randomly
picked tumors (range 5.2 mm
3–229 mm
3): 10/12 tumors exhibited
complete recombination, 1/12 showed partial recombination, and
1/12 had no recombination (Figure 4A and data not shown). Given
thefactthat theCretransgeneisnotefficientlyexpressedin10–20%
of the b-cells, and noting that the ratio of tumors with recombined
vs. non-recombined Bcl-x alleles was also ,10%, we conclude that
there was no selective growth advantage of Bcl-x
+/+ cells that
manifested itself in the clonal outgrowth of b-cells harboring non-
recombined alleles, in contrast to the situation with other genes that
have critical roles in RIP1-Tag2 tumorigenesis (e.g. VEGF [26]).
Notably, some of the largest tumors exhibited complete recombi-
nation, again supporting the notion that loss of Bcl-x function was
not impairing tumor growth. As another measure of recombination
efficiency, we assessed Bcl-x expression by quantitative RT-PCR
(Taqman) on first strand cDNA derived from 10 independent RIP1-
Tag2; RIP-Cre; Bcl-x
fl/fl tumors and 10 RIP1-Tag2; Bcl-x
fl/fl controls
(Figures 4B and S1). There was a significant reduction in Bcl-x
expression in 9/10 of the RIP1-Tag2; RIP-Cre; Bcl-x
fl/fl tumors
compared to RIP1-Tag2; Bcl-x
fl/fl controls, indicating that Bcl-x was
deleted in the majority of b-cells in these tumors. However, one
tumor expressed wild-type levels of Bcl-x, suggesting that it arose
from a b-cell that did not express Cre, and thus harbored a non-
recombined allele. This prediction was confirmed by screening all
10 of the RIP1-Tag2; RIP-Cre; Bcl-x
fl/fl tumors for Cre expression,
and as predicted this exceptional tumor did not express Cre, in
contrast to the 9 tumors that exhibited much reduced Bcl-x
expression (Figure 4C). Excluding this Cre-negative, Bcl-x-positive
‘‘escaper’’ tumor from analysis, the mean Bcl-x expression in ‘‘KO’’
tumors was 9.5-fold lower than that of controls. Thus, deletion of
Bcl-x in the b-cell compartment of these tumors resulted in a ,90%
reduction of Bcl-x expression, thereby confirming that the
preponderance of Bcl-x expression in RIP1-Tag2 tumors is b-cell
in originand that Cre was efficiently deleting Bcl-x withoutapparent
phenotypic consequence. The residual Bcl-x expression likely
originates from the stromal component of the lesions (principally
vascular and immune cell types), although we cannot formally rule
out the possibility that these tumors are oligo-clonal, and that some
of the residual Bcl-x mRNA is derived from relatively rare b-cells
harboring non-recombined Bcl-x alleles. To determine whether the
significant reduction of Bcl-x mRNA observed in bcl-x ‘‘KO’’
tumorsresultedinacommensuratereductioninBcl-x proteinlevels,
Figure 3. RIP1-Tag2 tumorigenesis is not dependent on Bcl-x
function. (A and B) Comparison of tumor volume and number.
Macroscopically visible tumors from 13 week old animals were excised,
attached exocrine tissue removed and measured with ruler. Tumor
volume was calculated using the formula V=(x * y
2)60.52. Data
represent Mean6SEM; +/+ and FL/+: n=7; FL/FL: n=24; RIP-Cre;Fl/Fl:
n=22. Statistical significance was determined by non-parametric T-test
(Mann-Whitney). P=0.98 (D) Apoptotic rate. Apoptotic cells were
quantified via TUNEL labeling of pancreatic sections from 13 week old
animals. Data represent Mean6SEM (n=5 mice/group). The percent
TUNEL
+ cells was calculated from sections of 16–17 individual tumors/
group. Statistical significance determined by non-parametric T-test
(Mann-Whitney). P=0.98.
doi:10.1371/journal.pone.0004455.g003
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RIP1-Tag2;RIP-Cre; Bcl-x
fl/fltumors. Consistent with thePCR-based
analysis of recombination and the quantitative RT-PCR analysis of
Bcl-x mRNA levels, Bcl-x protein levels were significantly reduced
compared to wild-type (w.t.) tumors (Figure 4D), indicating Cre-
mediated deletion of the Bcl-x locus in the vast majority of beta cells
of RIP1-Tag2;RIP-Cre; Bcl-x
fl/fl tumors. In addition, this result
confirms that the immunoreactive bands detected in normal islets
and RIP1-Tag2 lesions (Figure 1) were in fact derived from Bcl-x.
Together,the data supporttheconclusion that Bcl-xdoesnothavea
centralrole inmodulatingtumorapoptosis inthis pathway, and that
its function is either non-essential, redundant, and/or readily
compensated for by other genes, such as other anti-apoptotic
members of Bcl-2 family.
Figure 4. Bcl-x expression is ablated in the majority of RIP1-Tag2; RIP-Cre; Bcl-x
fl/fl tumors. (A) Efficient recombination of Bcl-x in RIP1-Tag2;
RIP-Cre; Bcl-x
fl/fl tumors. Genomic DNA was isolated from individual tumors from RIP1-Tag2; RIP-Cre; Bcl-x
fl/fl and RIP1-Tag2; Bcl-x
fl/fl mice. PCR was
carried out using a primer that binds upstream of the 59 loxP site and another primer that binds 39 to the downstream loxP site. The PCR fragment of
the non-recombined allele and the recombined allele are 2.9 kb and 150 bp, respectively. (B) Bcl-x expression is significantly reduced in Bclx-KO
tumors. Quantitative RT-PCR (Taqman) was carried out on 1
st strand cDNA synthesized from RNA isolated from individual tumors from RIP1-Tag2; RIP-
Cre; Bcl-x
fl/fl and RIP1-Tag2; Bcl-x
fl/fl. A spanning probe that detected all major anti-apoptotic splice variants was used. Gene expression was normalized
to and plotted as a function of GAPDH expression. (D) The RIP-Cre transgene is not expressed in RIP1-Tag2; RIP-Cre; Bcl-x
fl/fl tumors that retain Bcl-x
expression. Cre mRNA expression was monitored by RT-PCR on 1
st strand cDNA synthesized from RNA isolated from individual tumors from RIP1-
Tag2; RIP-Cre; Bcl-x
fl/fl and RIP1-Tag2; Bcl-x
fl/fl mice. Following 27 cycles of PCR, the cDNA was fractionated on agarose gels and visualized by ethidium
bromide staining. The PCR product is 520 bp. *non-recombined, Cre-negative tumor. (D) Bcl-x protein levels are significantly reduced in Bcl-x-KO
tumors, as revealed by Western blotting as in Figure 1. b-actin is used as a loading control.
doi:10.1371/journal.pone.0004455.g004
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tumorigenesis
Next, we sought to determine whether the 5 other known anti-
apoptotic members of the Bcl-2 family might be expressed during
RIP1-Tag2 tumorigenesis, thereby potentially compensating for
the absence of Bcl-x. We quantified Bcl-2, Bcl-w, A1, Mcl-1 and Boo
mRNA levels using quantitative RT-PCR analysis (Taqman) on 1
st
strand cDNA from normal islets (isolated from non-transgenic
mice), hyperplastic islets, angiogenic islets, and tumors from RIP1-
Tag2 mice. As shown in Figures 5 and S2, four of the genes were
expressed; the fifth, Boo, was not detected in some of samples and
was highly variable in replicate assays, consistent with its
expression being largely restricted to the male and female
reproductive organs [27]. Among the four expressed members,
only Bcl-w was expressed at levels comparable to Bcl-x. Expression
levels are presented relative to the control gene, GAPDH, which
exhibited the least variable expression compared to L19 and Gus
between normal islets and the different neoplastic islet lesions
(Figure S3). To determine if one or more of the anti-apoptotic Bcl-
2 family members was transcriptionaly up-regulated in the absence
of Bcl-x and therefore potentially functionally compensating for
the Bcl-x ‘‘knockout’’, we performed quantitative RT-PCR analysis
on the same 10 independent RIP1-Tag2; RIP-Cre; Bcl-x
fl/fl and 10
RIP1-Tag2; Bcl-x
fl/fl tumors in which Bcl-x expression was quantified
(in Figure 4B). There proved to be no significant difference in the
mRNA expression levels of these 5 genes (Figures 6 and S4).
Additionally, Taqman analysis of the same tumor cDNAs for up-
regulation of members of the IAP class of anti-apoptotic proteins
(CIAP1, CIAP2, Survivin, XIAP, and BRUCE) similarly failed to
reveal any significant transcriptional up-regulation of these genes in
the Bcl-x-KO tumors (data not shown).
Role of Bcl-x in modulating invasion in RIP1-Tag2
tumorignesis
In addition to modulating apoptosis in tumor cells, there have
been reports that Bcl-2 family members can additionally promote
carcinogenesis via effects on tumor cell invasion [28–31]. In one
report, a dissociation between the ability of Bcl-xL to modulate
apoptosis and invasiveness of human glioma cells was observed
[29]. More recently, up-regulation of Bcl-xL by somatic gene
transfer during RIP1-Tag2 tumorigenesis was reported to increase
invasiveness, without reducing apoptosis [32]. Motivated by these
results, and by the evident lack of effect of loss of Bcl-x on overall
RIP1-Tag2 tumor cell apoptosis and tumor burden, a potential
role for Bcl-x in tumor invasion was assessed. Tumors from RIP1-
Tag2; Bcl-x
fl/fl and RIP1-Tag2; RIP-Cre; Bcl-x
fl/fl mice were scored
as non-invasive, encapsulated tumors (IT) or invasive carcinomas
(IC1-microinvasive; IC2-highly invasive) according to the criteria
of Lopez and Hanahan [16]. Interestingly, there was a significantly
higher proportion of encapsulated, non-invasive tumors in RIP1-
Tag2; RIP-Cre; Bcl-x
fl/fl mice compared to RIP1-Tag2; Bcl-x
fl/fl mice
(22.8% vs. 4.3%; p,0.02) (Figures 7 and S5).
To substantiate the effect of loss of Bcl-x on invasion, cancer
cells with wild-type or deleted Bcl-x (bTC-Bcl-x-wt or bTC-Bcl-x-
knockout [KO]) were generated by deriving b-tumor cell lines
(‘‘bTC’’) from tumors of RIP1-Tag2; Bcl-x
fl/fl mice, and infecting
the cells with adenoviruses that do or do not express Cre (Ad-Cre-
GFP or Ad-GFP). Two weeks post-infection with Ad-Cre-GFP, the
levels of Bcl-x protein within the cell population were reduced by
approximately 75–80% (Figure 8A), likely reflecting recombina-
tion of the Bcl-x gene in the majority of cells; serum-starved cells
+/2Cre were seeded into the upper chambers of porous transwell
inserts either uncoated or Matrigel-coated to assess the effect of
loss of Bcl-x expression on migration and invasion, respectively. To
account for any potential differences in cell growth between bTC-
Bcl-x-wt or bTC-Bcl-x-KO cells over the time course of the
migration/invasion assays, equal numbers of cells were plated in
triplicate, and total cell numbers determined after a 48-hour
incubation. During this time period, there was no apparent
difference in cell growth between wild-type and Bcl-x-KO cells
(Figure 8B). This was consistent with the lack of effect of loss of
Bcl-x function on tumor growth and apoptosis in vivo. In addition,
there was no significant difference in the number of migrating or
invading cells along a serum gradient (Figure 8C,D). However, the
bTC cells were poorly invasive in these ex vivo assays, as reported
previously [32], in contrast to the common appearance of invasive
cancer cells during tumor progression. We wondered, therefore,
whether the typical cell culture conditions might not properly
model the invasion-inducing microenvironment in vivo. Notably,
various reports, including previous studies in the RIP1-Tag2
model, have demonstrated a role for hypoxia in stimulating tumor
invasion [33–36]. We therefore repeated the migration/invasion
assays in conditions mimicking hypoxia, by incorporating cobalt
chloride (CoCl2), which has been shown to induce biochemical
responses similar to those observed under low oxygen conditions
[37,38]. In this condition, overall cell survival was reduced
(Figure 8B) though the wild-type cells evidenced a 2-fold increase
in the number of migrating cells (p=0.006), and a 1.5-fold
increase in invading cells (p=0.07) (Figure 8C,D) relative to the
total number of surviving cells. A similar increase in migration was
observed in response to CoCl2 treatment of the bTC-Bcl-x-KO
cells (p=0.02) (Figure 8C); in contrast, these cells did not exhibit
increased invasion under these pseudo-hypoxic conditions, and
compared to the wild-type cells exhibited a modest yet significant
decrease (45%; p=0.005) in the relative number of invading cells
(Figure 8D). These data, consistent with the in vivo analysis,
suggest that while expression of multiple Bcl-2 family members
may render Bcl-x functionally redundant in terms of effects on
tumor cell apoptosis, Bcl-x may exhibit non-redundant and
distinct functions in regard to tumor invasiveness.
Discussion
In this study, we sought to determine whether genetic deletion
of one prominent anti-apoptotic member of the Bcl-2 family, Bcl-
x, would impact tumorigenesis. We demonstrate that Bcl-x is non-
essential for RIP1-Tag2 tumorigenesis, and that cells harboring
null alleles of Bcl-x do not have an inherent survival disadvantage
to cells expressing wild type Bcl-x. In addition, we demonstrate
that 4 of the other anti-apoptotic Bcl-2 family members, Bcl-2, Bcl-
w, A1 and Mcl-1 are reproducibly expressed in normal, non-
transgenic islets and throughout multistage tumorigenesis in RIP1-
Tag2 mice. Importantly, in tumors in which Bcl-x is deleted,
mRNA expression of these genes remains unchanged, suggesting
that Bcl-x in this tumor pathway is either non-essential, or
functionally redundant, and thus readily substituted without overt
transcriptional up-regulation of other members of this gene class.
Based on the quantitative RT-PCR experiments presented in this
study, a potential source of functional redundancy is Bcl-w, which
appears to be expressed at significantly higher levels than Bcl-2,
A1, Mcl-1 and Boo in both normal islets and lesional stages of the
RIP1-Tag2 tumor pathway.
Our results are consistent with a recent study demonstrating
that Bcl-2 is not strictly required for the development of myc
induced lymphomas in Eu-myc transgenic mice [39]. Whereas
previous studies had shown that myc plus over-expression of Bcl-2
synergized to accelerate lymphomagenesis in the Eu-myc model
Bcl-x and Islet Cell Tumors
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phenotype. Similarly, in contrast to the loss of function studies
presented above, forced over-expression of bcl-xL via a RIP7-Bcl-xL
transgene has a profound effect on RIP1-Tag2 tumorigenesis, in
that tumor progression is accelerated and tumor burden increased
in the double transgenic mice [15]. This augmentation of
tumorigenesis is accompanied by a significant decrease in the
apoptotic rate. Similar results have been obtained in a model of
Figure 5. Expression of anti-apoptotic Bcl-2 family members in the stages of islet tumor development. The mRNA levels of the pro-
survival Bcl-2 family members Bcl-x, Bcl-2, Bcl-w, A1, Mcl-1 and Boo were assessed using quantitative RT-PCR (Taqman) on first strand cDNA
synthesized from total RNA pools (4–6 animals per pool) of normal, non-transgenic islets, and of hyperplastic islets, angiogenic islets, and tumors
from RIP1-Tag2 mice. Gene expression was normalized to and plotted as a percentage of GAPDH expression.
doi:10.1371/journal.pone.0004455.g005
Bcl-x and Islet Cell Tumors
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wherein upregulation of bcl-xL is obligatory for myc-induced islet
tumorigenesis [20]. These data indicate that bcl-xL is a potent anti-
apoptotic gene and tumor progression factor when up-regulated/
over-expressed during lymphoid and pancreatic islet tumorigen-
esis, but that its anti-apoptotic functions are in some circumstances
non-essential, likely due to the redundant functions of the other
expressed Bcl-2 family members.
Despite the evident redundancy of endogenous levels of Bcl-x in
impacting apoptosis and tumor growth, a potentially distinct role
of Bcl-x in influencing tumor invasion was revealed by the
observation of an increased proportion of non-invasive adenomas
compared to invasive carcinomas in mice lacking Bcl-x expression
in the oncogene-expressing islet b-cells. This histopathological
implication is supported by experiments with islet tumor cell lines
lacking Bcl-x expression. The Bcl-x-null cells exhibited a decreased
capability to invade under conditions mimicking hypoxia; in
contrast, when the same cells were assayed in normal conditions,
their invasiveness was comparable to Bcl-x proficient cancer cells.
This result suggests that while endogenous Bcl-x expression may
be redundant under normal conditions, it can play a distinct role
in stressed conditions (e.g. hypoxia, nutrient deprivation, chemo-
therapy).
Our findings implicating Bcl-x in invasion are notable in light of
a recent study by Du et al., who reported a significant increase in
the incidence of invasive carcinomas in RIP1-Tag2 mice
engineered to focally over-express Bcl-xL via retrovirus-mediated
somatic gene transfer into neoplastic lesions [32]. Interestingly, this
mode of up-regulating Bcl-xL did not affect the incidence of
apoptotic cells in the tumors, in contradistinction to the
aforementioned study in which the RIP-Bcl-xL transgene pro-
duced a decreased apoptotic index [15]; such phenotypic
differences may be explained by differences in the uniformity,
timing or levels of expression of Bcl-xL (the effect of the transgene-
mediated over-expression of Bcl-xL on tumor invasion was not
assessed in this earlier study). Our current investigation now
provides additional, complimentary data to that of Du et al in
regard to this emergent function for Bcl-x, by demonstrating that
endogenous Bcl-x, in the absence of overt over-expression, can
influence tumor invasion.
Therapeutics that engage programmed cell death in tumor cells
have promise for the treatment of cancer. Indeed compounds that
broadly fall into this class have entered clinical development. ABT-
737, a BH3 mimetic, is one example [41]. Recently, it has been
reported that ABT-737 is not cytotoxic to all tumors cells, and that
‘‘chemoresistance’’ to ABT-737 is dependent on appreciable levels
of Mcl-1 expression, the one Bcl-2 family member it does not
effectively inhibit [42,43]. Indeed, suppression of Mcl-1 protein
levels by shRNA knockdown or indirect pharmacological
downregulation sensitizes resistant tumor cells to ABT-737
mediated cell death [44,45]. Collectively, the data suggest that
activity among the pro-survival Bcl-2 family members is, in certain
settings, functionally redundant, and that tumor cells utilize
multiple Bcl-2 family members for survival and proliferation. The
prediction follows that treatment of the RIP1-Tag2 mice with pan-
Bcl inhibitors will disrupt tumor growth if indeed, (as expected)
these genes cooperate in modulating the propensity for apoptosis
as an intrinsic barrier to tumorigenesis. It will be of additional
interest to ascertain whether such Bcl inhibitors can also restrict
tumor invasion and malignancy, endpoints that could be of
relevance in the clinical setting.
Materials and Methods
Real-time Q-PCR Analysis
Quantitative PCR was performed essentially as in Elson et
al.[46] In brief, RNA was extracted using Qiagen RNase Easy as
per manufacturer’s instructions. RNA concentration was deter-
mined by spectrophotometer (NanoDrop, Rockland, DE). RNA
quality was confirmed using a Bioanalyser (Agilent Technologies,
Palo Alto, CA). Total RNA was incubated with DNase (DNA-free,
Ambion, Austin, TX) to remove contaminating DNA. The DNase
Figure 7. Loss of Bcl-x expression results in an altered proportion of adenomas and carcinomas. Tumors in H&E-stained sections from
13 wk RIP1-Tag2; Bcl-x
fl/fl (n=46 tumors from 5 mice) and RIP1-Tag2; RIP-Cre; Bcl-x
fl/fl mice (n=35 tumors from 5 mice) were scored as either non-
invasive islet tumors/adenomas (IT) or invasive carcinomas (either IC1 or IC2) and the proportion of tumors in each class was calculated. Distribution
of tumors types was compared between the two groups using Fisher’s exact test. p=0.017.
doi:10.1371/journal.pone.0004455.g007
Figure 6. Loss of Bcl-x does not elicit transcriptional up-regulation of other anti-apoptotic Bcl-2 family members. The mRNA levels of
Bcl-x, Bcl-2, Bcl-w, A1, Mcl-1 and Boo were assessed using quantitative RT-PCR (Taqman) on first strand cDNA synthesized from total RNA isolated from
individual tumors from RIP1-Tag2; RIP-Cre; Bcl-x
fl/fl (n=9 tumors from 5 mice; 1 tumor found to not express Cre and exhibit wild-type levels of Bcl-x
excluded from these data) and RIP1-Tag2; Bcl-x
fl/fl mice (n=10 tumors from 5 individual mice). Relative gene expression was normalized to and
presented as a percentage of GAPDH expression. Data represents mean6SEM. Statistical significance determined by non-parametric T-test (Mann-
Whitney). P,0.05 considered significant.
doi:10.1371/journal.pone.0004455.g006
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specifications. ‘No Reverse transcriptase’ controls were performed
on all samples to confirm that genomic DNA was not present.
RNA was reverse transcribed into cDNA with iScript (Bio-Rad,
Hercules CA), 300 ng in a 20 ul volume according to manufac-
turer’s specifications. Quantitative-PCR analysis was performed
on an AB Prism 7900 or 7700 sequence detection system (Applied
Biosystems, Foster City, CA). Quantitative detection of specific
nucleotide sequences was based on the fluorogenic 59 nuclease
assay, and relative expression was calculated as previously
described [46]. Assays were designed (using Primer Express
software v1.5, Applied Biosystems) with 6-FAM fluorophore on
the 59 end and the quencher BHQ1 on the 39 end and reactions
were optimized to have .90% efficiency [or purchased as Assays–
on-Demand from Applied Biosystems(AB)]. Primer and probe
concentrations of 500 nM and 200 nM, were used respectively.
Figure 8. Effect of Bcl-x gene knockout on in vitro migration and invasion of tumor cells. bTC-Bcl-x
fl/fl tumor cells were infected with
adenovirus expressing Cre or control GFP and plated in triplicate in the presence or absence of cobalt chloride to assess the effect of reduced Bcl-x
expression on cell migration and invasion. (A) Western blot of Bcl-x and actin protein levels in bTC-Bcl-x
fl/fl cells treated +/2Cre at time of migration/
invasion assays. (B) Cell growth. 2610
5 bTC-Bcl-x
fl/fl cells +/2cre were plated in the presence or absence of CoCl2 and cells were counted after
48 hours. (C and D) Cell migration and invasion assays. Cells were plated in control trans-well inserts (C) or Matrigel-coated inserts (D). For the
migration assay, results are plotted as the mean number of migrating cells/106field (8 fields/membrane counted), while for the invasion assays the
total number of invading cells/membrane are plotted. CoCl2 treatment resulted in a significant decrease in invasion of bTC-Bcl-x-KO cells compared
to wild-type cells (P=0.005). Results shown represent the mean6SEM of results from three independent experiments performed in triplicate and are
corrected for changes in total cell number (from B) compared to control cells (-Cre, -CoCl2).
doi:10.1371/journal.pone.0004455.g008
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triplicate by real time PCR using QPCR master mix with final
concentrations 5.5 mM MgCl2, 200 uM dNTPs and 0.5units
Hotstart Amplitaq Gold (AB) in 20 ul volume 384 well plate or
50 uL volume for 96 well plates. For normalization, cDNA
equivalent to 3–5 ng input RNA was measured for GAPDH, L19
and Gus. GAPDH expression was the least variable under these
experimental conditions (Figure S3).
For the detection of transcriptional target messages, the
following primer and probe sets were used: pan-Bcl-x: ABI Assay
on Demand (AOD) Mm00437783_m1; Bcl-w: AOD
mM00432054_m1; Bcl-2: AOD Mm00477631_m1; Mcl-1: AOD
Mm00725832_s1; A1: AOD Mm00833201_s1; Boo: AOD;
Mm00478988_m1.
Transgenic mice breeding
The generation of RIP1-Tag2 mice as a model of pancreatic
islet cell carcinogenesis has been previously reported [13]. RIP2-
Cre transgenic mice, kindly provided by Mark Magnuson
(Vanderbilt University Medical Center, Nashville, TN) [23], were
previously backcrossed into the C57-Bl/6J background for more
than 15 generations. Bcl-x-floxed allele animals (mixed C57BL/6–
129SvEv background) were previously described [25,47]. They
were backcrossed into the C57-Bl/6J background for 5 genera-
tions, then crossed with the RIP-Tag2 and the RIP2-Cre in a Bcl-
x
fl/wt heterozygous background and then intercrossed to Bcl-x
fl/fl
animals to obtain RIP-Tag2; RIP2-Cre; Bclx
fl/fl animals. All
experiments involving mice were approved by the University of
California, San Francisco (UCSF) institutional review board.
Tissue preparation and immunohistochemistry
Normal (from non-transgenic C57Bl/6 mice), hyperplastic islets
(from 4–6 wk RIP1-Tag2 mice; not red), and angiogenic islets
(from 8–10 wk RIP1-Tag2 mice; red, with evident hemorrhages)
were isolated as previously described [48]. Tumors were carefully
microdissected away from the surrounding exocrine pancreas
tissue of freshly excised pancreata (from 12–13 wk RIP1-Tag2
mice). For protein analysis, tissue was disrupted in RIPA buffer
containing a protease inhibitor cocktail (Roche); western blotting
was performed using antibodies to Bcl-x (Pharmingen) and b-actin
(Sigma) for a loading control. For immunohistochemical analysis,
mice were anesthetized with tribromoethanol (Sigma) and heart-
perfused with PBS and then 10% zinc-buffered formalin (Medical
Chemical Corp.). Pancreata were removed and post-fixed in 10%
zinc-buffered formalin overnight and processed for paraffin
embedding as previously described [16]. TUNEL staining and
H&E grading were performed as previously described [16,26].
TUNEL quantification was performed on tumor-containing
sections (5 mm paraffin) from at least 5 mice per group. Statistical
analysis was performed using the non-parametric t-test (Mann-
Whitney) and p values of less than 0.05 were considered
statistically significant. For tumor grading, paraffin blocks from
pancreases of 5 mice/group were sectioned and 5 slides 50 mm
apart were stained by H&E. Tumors were blindly graded as either
encapsulated, non-invasive tumors (IT) or invasive carcinoma type
1 or 2 (IC1,2) as described [16]. Differences in the proportion of
IT and IC tumors in the two different genotypes were assessed by
Fisher’s exact test and a p value of less than 0.05 was considered
statistically significant.
Determination of tumor burden
Quantification of tumor burden was determined as previously
described [49]. Briefly, tumors were microdissected and tumor
dimensions were measured with a ruler, and tumor volume was
calculated using the formula [volume=width
26length60.52] to
approximate the volume of spheroid. Tumor burden per mouse
was calculated as the sum of the volumes of all tumors per mouse.
Statistical significance was determined by non-parametric T-test
(Mann-Whitney) and p values of less than 0.05 were considered
statistically significant.
In vitro migration and invasion assays
A bTC bcl-x
fl/fl cell line (#14731) was derived from a tumor of a
RIP1-Tag2; Bcl-x
fl/fl mouse. Briefly, the dissected tumor was
disrupted in DMEM supplemented with 20% fetal bovine serum
(FBS), penicillin/streptomycin, and fungizone and tumor cells
were collected by gravity sedimentation. Cells were infected with
either Ad-GFP or Ad-Cre-GFP (Vector Development Lab, Baylor
College of Medicine) at a multiplicity of infection of ,200.
Approximately two weeks post-infection, cells were serum-starved
overnight and 1610
5 cells were seeded the next day in triplicate
into BD BioCoat control trans-well inserts with 8-mm porous
polyethelene terepththalate (PET) membranes (for migration
assays) or Matrigel-coated invasion chambers (BD Biosciences).
Cells were plated in serum-free DMEM containing 0.2% bovine
serum albumin +/2100 mM cobalt chloride into the upper
chambers and the lower chambers were filled with DMEM (+/
2100 mM CoCl2) containing 10% FBS as a chemoattractant.
Cells were incubated for 48 hours in a humidified 5% CO2/37uC
incubator after which non-migrated/invaded cells were removed
from the upper membrane and membranes were fixed and stained
with 0.2% crystal violet. For quantitating migration, the mean
number of migrating cells in eight, 106 fields was determined/
membrane; for quantitating invasion, the total number of invading
cells/membrane was counted (under 106objective) due to the low
number of invading cells. To determine whether differences in cell
growth/survival as a result of reduced Bcl-x expression and/or
CoCl2 treatment could be contributing to the migration/invasion
results, in parallel with plating cells for the migration/invasion
assays, 2610
5 bTC Bcl-x
fl/fl cells +/2Ad-Cre were plated in
triplicate in 24-well plates (+/2CoCl2) and cells were trypsinized
and counted after 48 hrs. The migration/invasion and cell growth
assays were repeated in three separate experiments. With each
experiment, the same bTC Bcl-x
fl/fl cells +/2cre were also plated
for generation of protein extracts to confirm reduced Bcl-x protein
expression.
Supporting Information
Figure S1 Bcl-x expression is significantly reduced in Bclx-KO
tumors. Quantitative RT-PCR (Taqman) was carried out on 1st
strand cDNA synthesized from RNA isolated from individual
tumors from RIP1-Tag2; RIP-Cre; Bcl-xfl/fl and RIP1-Tag2; Bcl-
xfl/fl mice. A pan probe that detected all major anti-apoptotic
splice variants was used. Gene expression was normalized to and
plotted as a function of GUS (A) or L19 expression (B).
Found at: doi:10.1371/journal.pone.0004455.s001 (0.13 MB TIF)
Figure S2 Expression of anti-apoptotic Bcl-2 family members
during RIP1-Tag2 tumor development. mRNA levels of individ-
ual pro-survival Bcl-2 family members, Bcl-w, A1, Mcl-1 and Boo
were assessed using quantitative RT-PCR (Taqman) on first strand
cDNA synthesized from total RNA pools (4–6 animals per pool) of
normal, non-transgenic islets, hyperplastic islets, angiogenic islets,
and tumors from RIP1-Tag2 mice. Gene expression was
normalized to and plotted as a percentage of GUS (A) or L19
expression (B).
Found at: doi:10.1371/journal.pone.0004455.s002 (0.22 MB TIF)
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progression and in Bclx-w.t. and KO tumors. (A–C) mRNA levels
were assessed using quantitative RT-PCR (Taqman) on first strand
cDNA synthesized from total RNA pools (4–6 animals per pool) of
normal, non-transgenic islets (N), hyperplastic islets (H), angio-
genic islets (A), and tumors (T) from RIP1-Tag2 mice. Three
distinct Taqman primer sets were used to detect GAPDH, GUS
and L19. (D) Quantitative RT-PCR (Taqman) was carried out on
1st strand cDNA synthesized from RNA isolated from individual
tumors from RIP1-Tag2; RIP-Cre; Bcl-xfl/fl and RIP1-Tag2; Bcl-
xfl/fl mice.
Found at: doi:10.1371/journal.pone.0004455.s003 (0.18 MB TIF)
Figure S4 Loss of Bcl-x does not elicit transcriptional up-
regulation of other anti-apoptotic Bcl-2 family members. mRNA
levels of individual pro-survival Bcl-2 family members, Bcl-x, Bcl-
2, Bcl-w, A1, Mcl-1 and Boo were assessed using quantitative RT-
PCR (Taqman) on first strand cDNA synthesized from total RNA
isolated from individual tumors from RIP1-Tag2; RIP-Cre; Bcl-
xfl/fl mice (n=9 tumors from 5 distinct mice; 1 tumor found to
not express Cre and exhibit wild-type levels of Bcl-x excluded from
these data) and RIP1-Tag2; Bcl-xfl/fl mice (n=10 tumors from 5
individual mice). Relative gene expression was normalized to and
presented as a percentage of GUS (A) or L19 (B) expression. The
apparent up-regulation of bcl-w and mcl-1 when normalized to
L19 expression does not represent an actual change in Bcl-2 family
member expression but rather lower level of L19 in KO tumors
(Figure S3). Data represents Mean6SEM. Statistical significance
determined by non-parametric T-test (Mann-Whitney). P,0.05
considered significant.
Found at: doi:10.1371/journal.pone.0004455.s004 (0.20 MB TIF)
Figure S5 Loss of Bcl-x expression results in an altered
proportion of adenomas/carcinomas. Tumors on H&E sections
from 13 wk RIP1-Tag2; Bcl-xfl/fl (n=46 tumors from 5 mice) and
RIP1-Tag2; RIP-Cre; Bcl-xfl/fl mice (n=35 tumors from 5 mice)
were scored as either non-invasive islet tumors/adenomas (IT),
micro-invasive carcinomas (type 1; IC1), or highly invasive
carcinomas (type 2; IC2) and the proportion of tumors in each
class was calculated. p=0.04, Chi-squared test for independence,
comparing distribution of tumor types between the two groups of
mice.
Found at: doi:10.1371/journal.pone.0004455.s005 (0.12 MB TIF)
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